Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasm Metastasis 1Hematologic Neoplasms 1

Interventions

venetoclax 304Cyclophosphamide 229Cytarabine 199Azacitidine 187fludarabine 180Specimen Handling 136Biopsy 103fludarabine phosphate 97Methotrexate 81Rituximab 78Daunorubicin 77Dexamethasone 75Vincristine 68Whole-Body Irradiation 64Mycophenolic Acid 59Decitabine 57Tacrolimus 55Etoposide 52ibrutinib 51blinatumomab 51Granulocyte Colony-Stimulating Factor 51Busulfan 50obinutuzumab 49Prednisone 49Melphalan 48acalabrutinib 45Idarubicin 45Stem Cell Transplantation 44Injections 44Magnetic Resonance Spectroscopy 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Levorphanol × Other hematologic neoplasm × 1 year × Clear all
NCT03579446 2025-08-03

Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Terminated
43 enrolled
Other hematologic neoplasm

Neoplasm Metastasis, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡